Fibrinolytic Enzymes From Extremophilic Microorganisms in the Development of New Thrombolytic Therapies: Technological Prospecting.

MLA

Soares Bispo, James Romero, et al. “Fibrinolytic Enzymes From Extremophilic Microorganisms in the Development of New Thrombolytic Therapies: Technological Prospecting.” Recent Patents on Biotechnology, vol. 15, no. 3, 2021, pp. 169–83. EBSCOhost, https://doi.org/10.2174/1872208315666210805154713.

APA

Soares Bispo, J. R., de Oliveira Lima, I. G., da Silva, M. B., de Oliveira Feitosa, A., Dos Santos, A. C. M., Alexandre Moreira, M. S., Zambrano Passarini, M. R., Saraiva Câmara, P. E. A., Rosa, L. H., Oliveira, V. M., de Queiroz, A. C., & Fernandes Duarte, A. W. (2021). Fibrinolytic Enzymes From Extremophilic Microorganisms in the Development of New Thrombolytic Therapies: Technological Prospecting. Recent Patents on Biotechnology, 15(3), 169–183. https://doi.org/10.2174/1872208315666210805154713

Chicago

Soares Bispo, James Romero, Igor Gomes de Oliveira Lima, Maurício Bernardo da Silva, Alexya de Oliveira Feitosa, Ana Caroline Melo Dos Santos, Magna Suzana Alexandre Moreira, Michel Rodrigo Zambrano Passarini, et al. 2021. “Fibrinolytic Enzymes From Extremophilic Microorganisms in the Development of New Thrombolytic Therapies: Technological Prospecting.” Recent Patents on Biotechnology 15 (3): 169–83. doi:10.2174/1872208315666210805154713.